Oracle: analytics benefits to unfold in stages

As EDC gives way to clinical software suites, users are looking for ways to create insights from the volumes of data collected via automated clinical trial systems. "They want to aggregate and cross-correlate data from different silos, to get the most actionable and valuable insights," says Kris Joshi, senior director at Oracle, at the recent Life Sciences Technology Insight conference in Boston.

Joshi says he expects life sciences R&D analytics to gain traction in phases. In the next one to two years, users will gain business insights from existing data, culled primarily from operations reporting systems. In two to four years, users will become able to foresee problems and take proactive mitigation actions. And in three to five years, he expects users will be able to leverage business insights to drive innovation, via integrated content, analytics and workflow applications.

He also notes that secondary uses of clinical data (eg, cohort identification, safety profiles) are becoming popular requests among customers. And those customers, he says, want 80 percent of a solution prebuilt, ready for use out of the box. They also want solutions to use standard models and metrics around safety and quality of care, and to deliver analytics specific to various corporate functions.

- here's coverage of Oracle's Clinical Development Analytics offering

Relatecd Articles:
Oracle BI system: CDA vs. CTMS
US Oncology automates via Oracle

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.